Protox Therapeutics to present TRIUMPH clinical study update

Download PDF Copy

Sep 9 2009

NewsGuard 100/100 Score

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference. The conference runs from Wednesday, September 9 through Friday, September 11 at the Palace Hotel in New York City. Dr. Merchant's presentation is at 9:10 a.m. ET on Friday, September 11 in the Garrison Salon on the 5th floor of the hotel and will be webcast live from Protox's website.

Dr. Merchant will present the corporate story and upcoming milestone highlights, including an update on TRIUMPH, a double-blinded placebo controlled Phase 2b study of PRX302 in patients with benign prostatic hyperplasia (BPH). Dr. Merchant will also be presenting 12-month data from the Phase 2a open-label BPH study.

Source: PROTOX THERAPEUTICS INC.

Posted in: Drug Trial News

Tags: Benign Prostatic Hyperplasia, Brain, Brain Cancer, Cancer, Healthcare, Hyperplasia, Placebo, Prostate Cancer, Receptor, Therapeutics

Comments (0)

Download PDF Copy

Suggested Reading

Liraglutide activates key brain circuits to trigger weight loss in obesity

Liraglutide activates key brain circuits to trigger weight loss in obesity

Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies

Scientists uncover two Crohn’s disease subtypes using lab-grown intestines, offering hope for personalized therapies

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

Vitamin D receptor activation slows cell overgrowth in pulmonary hypertension

60 years in the making: Nanoparticles revolutionize nucleotide delivery

60 years in the making: Nanoparticles revolutionize nucleotide delivery

A review of clinical features, diagnosis, and management of Mpox

A review of clinical features, diagnosis, and management of Mpox

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

Impact of glucagon-like peptide-1 receptor agonists on alcohol consumption

How can microdialysis benefit drug development?

How can microdialysis benefit drug development?

Gut health and diet: Keys to treating acne, alopecia, and dermatitis

Gut health and diet: Keys to treating acne, alopecia, and dermatitis

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

How viral persistence and immune dysfunction drive long COVID